会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 51. 发明申请
    • PRODUCTION OF A POLYMER COMPOSITION
    • 生产聚合物组合物
    • WO1996025452A1
    • 1996-08-22
    • PCT/GB1996000305
    • 1996-02-12
    • ZENECA LIMITEDLIDDELL, John, MacdonaldGEORGE, NeilTURNER, Peter, Deryck
    • ZENECA LIMITED
    • C08J03/03
    • C12P7/625C08G63/89C08J3/07C08J2367/04
    • A process of making a polyhydroxyalkanoate PHA latex comprises making a liquid-form solution of such PHA in a water soluble liquid and contacting that solution with water under shear. Suitably the solution is prepared at a temperature between the boiling point of water and 10 DEG C below the melting point of the PHA as measured by DSC for example by melt separating PHA from a microbiologicalsuspension thereof, dissolving it in the water soluble liquid, and then contacting the solution at over 100 DEG C with water at 50-95 DEG C. The water-soluble liquid may be for example 1,2-propandiol or a liquid more volatile than water such as ethanol, propanol or tertiary butanol. A surfactant may be present or added after contacting, for example one providing steric stabilisation such as an acrylic graft copolymer emulsifier.
    • 制备聚羟基链烷酸酯PHA胶乳的方法包括将这种PHA的液体形式的溶液制成水溶性液体,并在剪切下使该溶液与水接触。 适当地,溶液在沸点水和低于PHA熔点10℃之间的温度下制备,例如通过DSC测量,例如通过将PHA与其微生物悬浮液熔融分离,将其溶解在水溶性液体中,然后 在100℃以上的溶液与水在50-95℃下接触。水溶性液体可以是例如1,2-丙二醇或比水如乙醇,丙醇或叔丁醇更易挥发的液体。 在接触之后可以存在或加入表面活性剂,例如提供空间稳定剂的表面活性剂,例如丙烯酸接枝共聚物乳化剂。
    • 56. 发明申请
    • QUINAZOLINE DERIVATIVES
    • 喹诺酮衍生物
    • WO1996016960A1
    • 1996-06-06
    • PCT/GB1995002768
    • 1995-11-28
    • ZENECA LIMITEDBARKER, Andrew, John
    • ZENECA LIMITED
    • C07D403/04
    • C07D231/12C07D233/56C07D249/08
    • The invention concerns quinazoline derivatives of formula (I) wherein m is 1 or 2; each R includes hydrogen, halogeno, (1-4C)alkyl and (1-4C)alkoxy; n is 1, 2 or 3; each R includes hydrogen, hydroxy, halogeno and (1-4C)alkyl; and Ar is a 5- or 9-membered nitrogen-linked heteroaryl moiety containing up to four nitrogen heteroatoms, or Ar is a 5-, 6-, 9- or 10-membered nitrogen-linked unsaturated heterocyclic moiety containing up to three nitrogen heteroatoms which bears one or two substituents selected from oxo and thioxo; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.
    • 本发明涉及式(I)的喹唑啉衍生物,其中m为1或2; 每个R 1包括氢,卤代,(1-4C)烷基和(1-4C)烷氧基; n为1,2或3; 每个R 2包括氢,羟基,卤代和(1-4C)烷基; 并且Ar是含有至多四个氮杂原子的5-或9-元含氮连接的杂芳基部分,或Ar是含有至多三个氮杂原子的5-,6-,9-或10-元含氮连接的不饱和杂环部分 其具有一个或两个选自氧代和硫代的取代基; 或其药学上可接受的盐; 其制备方法,含有它们的药物组合物以及该化合物的受体酪氨酸激酶抑制性质用于治疗增殖性疾病例如癌症的用途。
    • 57. 发明申请
    • PYRIDAZINOQUINOLINE COMPOUNDS
    • 吡啶并喹啉化合物
    • WO1996015127A1
    • 1996-05-23
    • PCT/GB1995002613
    • 1995-11-08
    • ZENECA LIMITEDBARE, Thomas, MichaelCHAPDELAINE, Marc, JeromeDAVENPORT, Timothy, WayneEMPFIELD, James, RoyGARCIA-DAVENPORT, Laura, EnidJACKSON, Paul, FrancisMcKINNEY, Jeffrey, AlanMcLAREN, Charles, DavidSPARKS, Richard, Bruce
    • ZENECA LIMITED
    • C07D471/04
    • C07D471/04
    • The invention relates to pyridazinoquinoline coumpounds of formulae A and A', wherein: ring A is chosen from an ortho fused aromatic or heteroaromatic five- or six-membered ring; R is selected from the group consisting of halo, (1-4C)alkyl, NO2, CN, (C1-3)perfluoroalkyl, OH, OCF3, (2-4C)alkenyl, (2-4C)alkynyl, O(1-4C)alkyl, NR'R", SO2NR'R", or SOmR'; R is selected from H, (1-6C)alkyl, or -(CH2)nL; R is selected from H or -(CH2)nL; L is a variety of substituents including phenyl, heterocyclic groups and heteroaryl; n is 0-6; m is 0-2, R is selected from H, (1-6C)alkyl or (1-6C)alkylaryl; R is selected from H or -(CO)R wherein R is selected from a variety of substituents including hydrogen, (1-12C)alkyl, pyridyl, phenyl, pyridyl (1-12C)alkyl and phenyl (1-4C)alkyl; and R' and R" are selected from H, (1-4C)alkyl, (3-6C)cycloalkyl, phenyl (0-4)alkyl-, heterocycle (0-4C)alkyl- or heteroaryl (0-4C)alkyl- to pharmaceutical compositions containing them and to methods for the treatment of neurological disorders utilizing them.
    • 本发明涉及式A和A'的哒嗪喹啉基团,其中:环A选自邻近稠合芳族或杂芳族五元或六元环; R 4选自卤素,(1-4C)烷基,NO 2,CN,(C 1-3)全氟烷基,OH,OCF 3,(2-4C)烯基,(2-4C)炔基,O (1-4C)烷基,NR'R“,SO2NR'R”或SOmR'; R 1选自H,(1-6C)烷基或 - (CH 2)n L; R 2选自H或 - (CH 2)n L; L是各种取代基,包括苯基,杂环基和杂芳基; n为0-6; m为0-2,R 5选自H,(1-6C)烷基或(1-6C)烷基芳基; R 3选自H或 - (CO)R 6,其中R 6选自多种取代基,包括氢,(1-12C)烷基,吡啶基,苯基,吡啶基(1-12C)烷基 和苯基(1-4C)烷基; 并且R'和R“选自H,(1-4C)烷基,(3-6C)环烷基,苯基(0-4)烷基 - ,杂环(0-4C)烷基 - 或杂芳基(0-4C)烷基 - 含有它们的药物组合物和用于治疗利用它们的神经障碍的方法。
    • 58. 发明申请
    • HERBICIDAL PYRAZOLES
    • 除草剂PYRAZOLES
    • WO1996015116A1
    • 1996-05-23
    • PCT/GB1995002459
    • 1995-10-18
    • ZENECA LIMITEDCHRYSTAL, Ewan, James, TurnerBARNETT, Susan, Patricia
    • ZENECA LIMITED
    • C07D231/20
    • C07D231/22A01N43/56
    • Compounds of formula (I) wherein: R is hydrogen, alkyl, alkenyl or alkynyl, any of which may optionally be substituted; R is alkyl, alkenyl or alkynyl, any of which may optionally be substituted, or OR or SOmR ; R is H, halogen, cyano, optionally substituted alkyl, alkenyl or alkynyl or OR or CO2R ; R is H, alkyl, alkenyl or alkynyl, any of which may optionally be substituted, halogen, cyano, nitro, CO2R , OR , NR R , NR SO2R , OSO2R or OmSR R R ; R , R and R are each independently H or alkyl, alkenyl or alkynyl, any of which may optionally be substituted; Y is halogen or cyano; each X is independently halogen, cyano, nitro, hydroxy, alkyl, alkoxy, alkylthio, alkoxyalkyl, SOmalkyl, CONR R or heterocyclyl or, alternatively, two X groups together or an X group and R may form a further ring; m is 0, 1 or 2; n is 0, 1 or 2; R and R are each independently hydrogen or lower alkyl; are active as herbicides.
    • 式(I)的化合物,其中:R 1是氢,烷基,烯基或炔基,其中任何一个可以任选被取代; R 2是烷基,烯基或炔基,其中任何一个可任选被取代,或OR 5或SOmR 5; R 3是H,卤素,氰基,任选取代的烷基,烯基或炔基或OR 5或CO 2 R 5; R 4是H,烷基,烯基或炔基,其中任何一个可以任选被取代,卤素,氰基,硝基,CO 2 R 5,OR 5,NR 5 R 6,NR 5 SO 2 R 6,OSO 2 R 5或OmSR 5 R 6 R 7; R 5,R 6和R 7各自独立地为H或烷基,烯基或炔基,其中任何一个可任选被取代; Y是卤素或氰基; 每个X独立地是卤素,氰基,硝基,羟基,烷基,烷氧基,烷硫基,烷氧基烷基,SOm烷基,CONR 8 R 9或杂环基,或者两个X基团或X基团和R 4可以 形成另一个戒指; m为0,1或2; n为0,1或2; R 8和R 9各自独立地为氢或低级烷基; 作为除草剂具有活性。
    • 60. 发明申请
    • AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS
    • 作为抗生素或抗凝剂的氨基酸衍生物
    • WO1996010022A1
    • 1996-04-04
    • PCT/GB1995002285
    • 1995-09-25
    • ZENECA LIMITEDFAULL, Alan, WellingtonMAYO, Colette, MariePRESTON, JohnSTOCKER, Andrew
    • ZENECA LIMITED
    • C07D401/04
    • C07D213/74C07D401/04C07D401/12C07D401/14C07D405/14C07D409/14
    • The invention concerns compounds of formula (I), wherein each of G , G and G is CH or N; m is 1 or 2; R includes hydrogen, halogeno and (1-4C)alkyl; M is a group of formula: NR -L -T R , in which R and R together form a (1-4C)alkylene group, L includes (1-4C)alkylene, and T is CH or N; A may be a direct link; M is a group of the formula: (T R )r-L -T R in which R is 0 or 1, each of T and T is CH or N, each of R and R is hydrogen or (1-4C)alkyl, or R and R together form a (1-4C)alkylene group, and L includes (1-4C)alkylene; M may be a direct link to X; X includes sulphonyl; and Q includes naphthyl and a heterocyclic moiety; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.
    • 本发明涉及式(I)化合物,其中G 1,G 2和G 3各自为CH或N; m为1或2; R 1包括氢,卤素和(1-4C)烷基; M 1是下式的基团:NR 2 -L 1 -T 1 R 3,其中R 2和R 3一起形成(1-4C)亚烷基 ,L 1包括(1-4C)亚烷基,T 1是CH或N; A可能是直接链接; M 2是下式的基团:(T 2 R 4)r L 2 -T 3 R 5其中R是0或1,每个T 2和T R 3和R 5分别是氢或(1-4C)烷基,或者R 4和R 5一起形成(1-4C)亚烷基, 和L 2包括(1-4C)亚烷基; M 3可以直接连接到X; X包括磺酰基; 且Q包括萘基和杂环部分; 或其药学上可接受的盐; 其制备方法,含有它们的药物组合物及其作为抗血栓形成或抗凝血剂的用途。